DOI: 10.36347/sjams.2016.v04i01.002

Pages: 6-8

Abstract: Gastro oesophageal reflux disease (GERD) and dyspepsia are chronic gastric disorders, highly prevalent in Indian population. Pantoprazole is a well established PPI, which specifically inhibits the H+-K+-ATPase of gastric cells to suppress gastric acid secretion. Levo sulpiride is a neuroleptic and Dopamine D2-specific antagonist, which blocks presynaptic dopaminergic receptors at low doses resulting in decreased dopamine synthesis and release. This study was conducted to assess the symptomatic efficacy and tolerability of Pantoprazole and levo sulpiride combination in the management of GERD and dyspepsia in the Indian population. The settings and design was an observational, prospective, uncontrolled, open label, single centre study in Indian patients. The methods and materials were Total 1000 patients were enrolled in the study. Patients were prescribed Pantoprazole 40 milligram with levo sulpiride 75 milligram sustained release fixed dose combination orally daily for 28 days. The efficacy and tolerability assessment was performed on day 29-32 after beginning the treatment and recorded in the case report forms. The efficacy of Pantoprazole plus levo sulpiride combination was estimated on the changes from the baseline in the symptom score on a on a frequency scale for symptoms of GERD (FSSG). In results Pantoprazole and levo sulpiride combination effectively controlled GERD and dyspepsia symptoms in all patients and none of the patients showed worsening of the symptoms. The overall mean FSSG score decreased by 60.89%, from 18.88 to 8.28. Pantoprazole and levo sulpiride combination was well tolerated by 98.2 % patients. Only 1.8% patients did not tolerate Pantoprazole and levo sulpiride combination. In conclusion the present study demonstrates that Pantoprazole and levo sulpiride combination symptomatically controls GERD and dyspepsia with good tolerability.